Cipla Limited: Business Overview, Financials & Competitive Analysis
Cipla Limited scores 7/10 on the AskCyborg Cyborg Score (Strong). Strong market leadership and financial discipline offset near-term headwinds from US generic competition and profit margin compression. Cipla is almost debt-free and has delivered strong profit growth of 28.7% CAGR over the past 5 years with healthy dividend payouts. However, recent earnings misses and margin pressure offset strong market positions.
What is Cipla Limited's industry? Cipla Limited (cipla.com) operates in Pharmaceuticals - Generics, Specialty, Biosimilars, and Consumer Healthcare. AskCyborg classifies Cipla Limited under Pharmaceuticals - Generics, Specialty, Biosimilars, and Consumer Healthcare in its company registry.
Cipla Limited manufactures, develops, sells, and distributes pharmaceutical products in India, the United States, South Africa, and internationally. The company offers generic and branded generic medicines, vaccines, ...
Cyborg Score thesis
Strong market leadership and financial discipline offset near-term headwinds from US generic competition and profit margin...
Read the full analyst-debate transcript →Get the Latest Cipla Limited Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeCipla Limited Overview
Pro stress-test →Cipla Limited manufactures, develops, sells, and distributes pharmaceutical products in India, the United States, South Africa, and internationally. The company offers generic and branded generic medicines, vaccines, active pharmaceutical ingredients, and formulations across therapeutic areas, and is involved in consumer healthcare, biosimilars, and specialty businesses.
Strategic Profile
Pro stress-test →Cipla is the 3rd largest player in the private Rx market in South Asia and the fastest growing generic player in North America. The company holds leadership positions in respiratory care and top-5 rankings in urology and anti-infectives in the domestic market.
Competitive Landscape
Pro stress-test →Cipla operates in the Healthcare sector within Pharmaceuticals. The company competes with major Indian pharma players including Dr. Reddy's Laboratories, Sun Pharmaceutical, Lupin, and Aurobindo Pharma in generics and specialty segments, while facing North American competition in its growing US generic business.
Industry Context
Cipla Limited operates in Pharmaceuticals - Generics, Specialty, Biosimilars, and Consumer Healthcare.
Key facts
Founded: 1935 · Headquarters: Mumbai, India · Revenue: ~70.75B INR (Q3 FY26) · Market cap: ₹1.08 trillion (~$13B USD equivalent)